title: Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
abstract: In chronic myeloid leukemia (CML), cytogenetic abnormalities found in addition to the t(9;22) translocation may impact the response to therapy. Loss of the Y chromosome is generally overlooked in this context, owing to its relatively frequent occurrence in healthy elderly patients. In this multicenter retrospective study, the outcome after imatinib treatment of 30 CML patients with karyotype showing Y chromosome loss (Y-) was compared to 30 Y+ control males diagnosed and treated at the same time in the same institutions. Y- patients had significantly delayed cytogenetic and molecular responses, lower event-free survival and shorter overall survival than Y+ patients. The negative impact of this abnormality was particularly marked when it occurred in a sub-clone (clonal evolution) rather than in all mitoses. These data indicate that loss of the Y chromosome should be taken into account in the prognostic evaluation of chronic myelogenous leukemia patients.
authors.affiliation: Laboratoire d'Hématologie Hôpital Haut Lévêque, Avenue de Magellan, 33604 Pessac, France. eric.lippert@chu-bordeaux.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Lippert
authors.forename: Gabriel
authors.initials: G
authors.lastname: Etienne
authors.forename: Marie-Joelle
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: Sophy
authors.initials: S
authors.lastname: Laibe
authors.forename: Carine
authors.initials: C
authors.lastname: Gervais
authors.forename: Stéphane
authors.initials: S
authors.lastname: Girault
authors.forename: Nathalie
authors.initials: N
authors.lastname: Gachard
authors.forename: Isabelle
authors.initials: I
authors.lastname: Tigaud
authors.forename: Nicole
authors.initials: N
authors.lastname: Dastugue
authors.forename: François
authors.initials: F
authors.lastname: Huguet
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Fort
authors.forename: Laurence
authors.initials: L
authors.lastname: Legros
authors.forename: Virginie
authors.initials: V
authors.lastname: Eclache
authors.forename: Francois-Xavier
authors.initials: FX
authors.lastname: Mahon
mesh_terms: D001549:Benzamides; D002869:Chromosome Aberrations; D041322:Chromosomes, Human, Y; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate